Retrospective analysis of clinical cases of psoriasis related to immune checkpoint inhibitors
10.3760/cma.j.cn114015-20240418-00267
- VernacularTitle:免疫检查点抑制剂相关银屑病临床病例回顾性分析
- Author:
Huiyun WANG
1
;
Shan′ai SONG
;
Shuya LIANG
;
Zhongwei XIAO
;
Yu LIANG
;
Chuantao ZHANG
;
Ning LIU
;
Zimin LIU
;
Helei HOU
Author Information
1. 青岛大学附属医院肿瘤科，青岛 266005
- Publication Type:Journal Article
- Keywords:
Antineoplastic agents;
Immune checkpoint inhibitors;
Psoriasis;
Immune-related adverse reactions
- From:
Adverse Drug Reactions Journal
2024;26(12):743-748
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the clinical characteristics of immune-related psoriasis caused by immune checkpoint inhibitors (ICIs).Methods:The patients with newly developed or worsening psoriasis after ICIs treatment in Department of Oncology, the Affiliated Hospital of Qingdao University from November 2019 to October 2023 were enrolled in this study. The patients′ gender, age, tumor type and stage, usage and dosage of ICIs, drugs applied in combination, history of psoriasis, the time of new onset or deterioration, clinical manifestations, intervention measures and outcomes were collected, and descriptive statistical analysis was performed.Results:A total of 13 patients were enrolled in the study, including 10 males and 3 females, with a median age of 66 years. The primary diseases included lung cancer (in 7 patients), gastric cancer (in 5 patients), and cholangiocarcinoma (in 1 patient). The tumor stage was Ⅳ in 12 patients and Ⅲ in 1 patient. Ten patients were treated with programmed cell death 1 receptor (PD-1) inhibitors, 2 with programmed cell death ligand 1 (PD-L1) inhibitors, and one with a PD-1/cytotoxic T-lymphocyte-associated antigen 4 combination antibody. All 13 patients were treated with other anti-tumor drugs at the same time. There were 10 patients with a history of psoriasis and 3 patients with newly developed psoriasis. The median time from the use of ICIs to the onset or deterioration of psoriasis was 54 days. Ten patients were plaque psoriasis and 3 were drip psoriasis. Among the 13 patients, 5, 5, and 3 patients were classified as mild, moderate, and severe, respectively. ICIs treatment was suspended in 11 patients and not stopped in 2 patients. After treatment with glucocorticoids, the skin lesions of 13 patients were improved and ICIs were restarted in 3 patients.Conclusions:ICIs-related psoriasis usually occurs within 2 months after the use of ICIs. The clinical types are plaque-like and drop-like, mostly mild or moderate. The prognosis is good after discontinuing ICIs or giving glucocorticoids and other drugs. Some patients can restart ICIs treatment.
